GEO Group (GEO) Q3 2026 Earnings Call Transcript

GEO Group reported Q3 2026 revenue of $761.1 million, up 12% year over year, and record adjusted EBITDA of $145.3 million, up 21%; adjusted net income rose 48% to $51.8 million. The company raised 2026 guidance to $2.975–$3.025 billion in revenue and $568–$573 million in adjusted EBITDA, and said 2027 growth is expected from new ICE facility activations and expanded service contracts. GEO sold its Adelanto complex for $950 million, used $650 million of proceeds to redeem senior secured notes, and increased its share repurchase authorization to $1.25 billion; management is negotiating potential sales of up to four more facilities, but no agreements are in place.

Analysis

The important change is capital intensity, not simply faster growth: GEO is trying to monetize facilities while retaining service contracts. That can improve balance-sheet flexibility and reduce property exposure, but the earnings quality depends on contract economics after ownership-related payments fall away; management has not quantified the resulting margin change. Likewise, the announced repurchase authorization is capacity, not evidence of execution. Watch actual share count reduction and cash allocation after any further sales.

Near term, the completed sale and debt reduction lower refinancing risk; over 1–3 months, potential additional sales and procurement awards are catalysts, but management says no further sale is definitive. The 2027 facility activations offer a route to higher revenue, yet timing, staffing and contract-level profitability remain execution risks. ICE concentration makes GEO unusually sensitive to appropriations, enforcement priorities, procurement delays and court or policy changes. A shift from detention toward alternatives could support monitoring services, but the call gives no basis to assume that offsets detention volatility in earnings.

Contrarian point: the large addressable funding pool and idle-bed revenue estimate can make upside look more certain than it is. Funding availability is not the same as awards, occupancy or profitable utilization; reimbursement of activation capex also does not establish attractive ongoing margins. Treat the transcript’s guidance and forward-looking figures as company claims and verify against filings, particularly given apparent transcription inconsistencies.

Key Decisions for Investors

• Construct a measured long GEO position on weakness rather than chase the results; the balance-sheet reset and contracted growth support the thesis, but valuation and current price are not provided, so size against portfolio risk rather than an implied target.
• Use additional asset sales as a catalyst, not a base-case assumption. Add only after definitive agreements disclose price, retained-service terms and expected proceeds; verify whether proceeds produce completed buybacks or further debt reduction.
• Track 2027 activation milestones and quarterly operating metrics: facility start dates, occupancy, adjusted EBITDA conversion, unreimbursed capex and cash flow. Delays, weaker margins, or guidance cuts would falsify the growth thesis.
• Avoid a GEO-versus-CXW pair based on this call alone: it supplies no comparable CoreCivic earnings or valuation evidence. Reassess the peer trade if CXW reports directly comparable contract wins or facility-sale economics.